Luye Pharma Group Ltd
HKEX:2186

Watchlist Manager
Luye Pharma Group Ltd Logo
Luye Pharma Group Ltd
HKEX:2186
Watchlist
Price: 3.88 HKD 1.04% Market Closed
Market Cap: 14.6B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Luye Pharma Group Ltd

Wall Street analysts forecast Luye Pharma Group Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Luye Pharma Group Ltd is 3.24 HKD with a low forecast of 3.13 HKD and a high forecast of 3.41 HKD.

Lowest Forecast
Wall Street Target
3.13 HKD
19% Downside
Average Forecast
Wall Street Target
3.24 HKD
17% Downside
Highest Forecast
Wall Street Target
3.41 HKD
12% Downside
Lowest
Price Target
3.13 HKD
19% Downside
Average
Price Target
3.24 HKD
17% Downside
Highest
Price Target
3.41 HKD
12% Downside
Luye Pharma Group Ltd Competitors:
Price Targets
4506
Sumitomo Pharma Co Ltd
35% Downside
SAN
Sanofi SA
35% Upside
H
293480
Hana Pharm Co Ltd
37% Upside
1477
Ocumension Therapeutics
17% Downside
4506
Sumitomo Pharma Co Ltd
35% Downside
SAN
Sanofi SA
35% Upside
H
293480
Hana Pharm Co Ltd
37% Upside
1477
Ocumension Therapeutics
17% Downside

Revenue
Forecast

Revenue Estimate
Luye Pharma Group Ltd

For the last 8 years the compound annual growth rate for Luye Pharma Group Ltd's revenue is 10%. The projected CAGR for the next 3 years is 10%.

10%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Luye Pharma Group Ltd

For the last 8 years the compound annual growth rate for Luye Pharma Group Ltd's operating income is 5%. The projected CAGR for the next 3 years is 14%.

5%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Luye Pharma Group Ltd

For the last 8 years the compound annual growth rate for Luye Pharma Group Ltd's net income is -8%. The projected CAGR for the next 3 years is 26%.

-8%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Luye Pharma Group Ltd's stock price target?
Price Target
3.24 HKD

According to Wall Street analysts, the average 1-year price target for Luye Pharma Group Ltd is 3.24 HKD with a low forecast of 3.13 HKD and a high forecast of 3.41 HKD.

What is Luye Pharma Group Ltd's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Luye Pharma Group Ltd's revenue is 10%. The projected CAGR for the next 3 years is 10%.

What is Luye Pharma Group Ltd's Operating Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Luye Pharma Group Ltd's operating income is 5%. The projected CAGR for the next 3 years is 14%.

What is Luye Pharma Group Ltd's Net Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Luye Pharma Group Ltd's net income is -8%. The projected CAGR for the next 3 years is 26%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 273,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.